KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Common Equity (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Common Equity for 13 consecutive years, with $581.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 22.94% to $581.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $581.8 million, a 22.94% decrease, with the full-year FY2025 number at $581.8 million, down 22.94% from a year prior.
  • Common Equity was $581.8 million for Q4 2025 at Xenon Pharmaceuticals, up from $559.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $927.9 million in Q4 2023 to a low of $248.9 million in Q3 2021.
  • A 5-year average of $639.8 million and a median of $666.7 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 220.99% in 2021, then decreased 29.87% in 2025.
  • Xenon Pharmaceuticals' Common Equity stood at $550.0 million in 2021, then soared by 31.17% to $721.5 million in 2022, then increased by 28.61% to $927.9 million in 2023, then dropped by 18.65% to $754.9 million in 2024, then dropped by 22.94% to $581.8 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Common Equity are $581.8 million (Q4 2025), $559.5 million (Q3 2025), and $634.0 million (Q2 2025).